DS
XGN icon

David Shaw’s Exagen XGN Stock Holding History

David Shaw’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231K Buy
49,712
+15,143
+44% +$57K ﹤0.01% 4518
2026
Q1 		$104K Buy
34,569
+2,990
+9% +$11.6K ﹤0.01% 4284
2025
Q4 		$192K Buy
+31,579
New +$287K ﹤0.01% 4340

Other funds holding XGN

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

David Shaw's XGN Position: Q2 2026 in Review

David Shaw increased its Exagen (XGN) stake by 44% in Q2 2026, buying an estimated $57K and bringing the position to 49,712 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #4518.

David Shaw first reported a position in XGN in Q4 2025 and has held it in 3 quarters since. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • David Shaw held 49,712 shares of Exagen worth $231K as of Q2 2026.
  • David Shaw bought 15,143 Exagen shares in Q2 2026, an estimated $57K.
  • Exagen made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4518 holding.
  • David Shaw first reported a position in Exagen in Q4 2025 and has held it in 3 quarters since.
  • 57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.